KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA (2016 - 2025)

Historic EBITDA for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $148.6 million.

  • Medpace Holdings' EBITDA rose 2444.09% to $148.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.5 million, marking a year-over-year increase of 2261.45%. This contributed to the annual value of $474.7 million for FY2024, which is 3150.65% up from last year.
  • Medpace Holdings' EBITDA amounted to $148.6 million in Q3 2025, which was up 2444.09% from $133.1 million recorded in Q2 2025.
  • In the past 5 years, Medpace Holdings' EBITDA ranged from a high of $148.6 million in Q3 2025 and a low of $46.4 million during Q2 2021
  • Its 5-year average for EBITDA is $92.1 million, with a median of $91.2 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 80.42% in 2021, then skyrocketed by 4329.14% in 2022.
  • Quarter analysis of 5 years shows Medpace Holdings' EBITDA stood at $59.0 million in 2021, then skyrocketed by 38.04% to $81.5 million in 2022, then grew by 15.02% to $93.7 million in 2023, then skyrocketed by 41.37% to $132.5 million in 2024, then rose by 12.15% to $148.6 million in 2025.
  • Its EBITDA stands at $148.6 million for Q3 2025, versus $133.1 million for Q2 2025 and $120.2 million for Q1 2025.